Response of metastatic epidermoid anal cancer to single agent irinotecan: A case report

Tumori

Volumn 87, Issue 1, 2001, Pages 58-59

  Grifalchi, F ^a   Padovani, A ^a   Romeo, F ^a   Trinca, C ^a   Moscetti, L ^a   Cortesi, E ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anal cancer; Irinotecan

Indexed keywords

CISPLATIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C;

ADULT; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DOSE RESPONSE; FEMALE; HUMAN; LIVER METASTASIS; METASTASIS; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

EID: 0035063075     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160108700113     Document Type: Article

References (16)

1. Malignant tumors of the anal canal. The spectrum of disease, treatment and outcomes
2. Carcinoma of the anal region
3. Response of metastatic cloacogenic carcinoma to treatment with semustine
4. Prognosis of cloacogenic and squamous cancers of the anal canal
5. Combined therapy for cancer of the anal canal: A preliminary report
6. Cisplatin and 5FU as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal
7. Dynamic management of squamous cell cancer of the anal canal
8. Treatment of relapsing anal carcinoma
9. Metastatic cloacogenic carcinoma of the anus: Sequential responses to adriamycin and cis-dichlorodiammineplatinum
10. Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma
11. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: A report of two cases
12. Regression of pulmonary metastases from cloacogenic carcinoma after cisplatinum/5FU treatment
13. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal
14. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal
15. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
16. CPT-11: An original spectrum of clinical activity